A Phase II Open-label, Parallel Group Study of Abiraterone Acetate Plus Prednisone in African American and Caucasian Men With Metastatic Castrate-resistant Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- 08 Aug 2017 Planned End Date changed from 1 Mar 2018 to 1 Oct 2018.
- 08 Aug 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Oct 2018.
- 10 Jun 2017 Biomarkers information updated